| Revenue Growth | Innovative up 33%; US Generics down 3%; EU Generics up 7%. |
|---|---|
| Mgmt Confidence | High confidence in achieving $2.5B Austedo target one year early. |
| Demand Visibility | Austedo US TRX up 18%; Uzedy TRX up 62% year-over-year. |
| Margin Trends | Non-GAAP gross margin 58.7%, up 245 bps; operating margin 31.7%. |
| Op. Leverage | Structural cost savings and productivity improvements driving 30% operating margin target. |
| Pricing Power | Austedo pricing environment noted as challenging ahead of 2027 IRA implementation. |
| Vol vs Price | Growth driven by innovative product mix and volume; generics revenue declined. |
| Segment Growth | Innovative portfolio accelerating; Biosimilars on track for $800M by 2026. |
| New Clients | Strengthened partnership with Samsung for two FDA-approved TNF alpha biosimilars. |
| Capex & Debt | Repaid $1.8B debt in October; net debt to EBITDA target 2x. |
| Regulatory | FDA Fast Track for KTR-15; discontinued Emersonalmen study due to futility. |
| Commentary | Transitioning from a generic-driven company to a high-margin biopharma powerhouse. |
| New Launches | Launched Welltruza for schizophrenia; acquired BXCL-501 for acute agitation. |
Growth
Innovative portfolio up 33%; Austedo grew 21% to $751M; Uzedy up 96% to $85M.
Outlook
Targeting $2.5B-$2.65B Austedo sales in 2026 and 30% operating margin by 2027.
Risks
Management pivoted on specific 2027 Austedo IRA impacts and Symphony biosimilar litigation timelines.
The company's earnings call, NYSE: TEVA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Teva Pharmaceutical Industries Ltd: key numbers
- Share price
- $42.57Close, Nov 16
- Market cap
- $49.7B
- Shares outstanding
- 1.17BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Teva Pharmaceutical Industries Ltd
All →Teva Pharmaceutical Industries EVP, Europe Commercial Richard Daniell Sells $1.93M of Stock
Richard Daniell, EVP, Europe Commercial, sold 45,003 shares of Teva Pharmaceutical Industries Ltd at $42.80 to $42.91 a share (average $42.86) in 2 transactions, worth $1.93M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 55,755 (-26.4%).
- Value
- $1.93M
- Shares
- 45,003
- Average price
- $42.86
- Role
- EVP, Europe Commercial
- Holding change
- -26.4%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Teva Pharmaceutical Industries President and CEO Richard D. Francis Sells $10.6M of Stock
Richard D. Francis, President and CEO, sold 250,000 shares of Teva Pharmaceutical Industries Ltd at $42.24 a share, worth $10.6M in total on Nov 10, 2026. Shares held after the trade: 927,529 (-21.2%).
- Value
- $10.6M
- Shares
- 250,000
- Price
- $42.24
- Role
- President and CEO
- Holding change
- -21.2%
- Trade date
- Nov 10, 2026
Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock
Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).
- Value
- $1.97M
- Shares
- 44,710
- Price
- $44.14
- Role
- See "Remarks"
- Holding change
- -35.6%
- Trade date
- Nov 12, 2026
Teva Pharmaceutical Industries CAO Amir Weiss Sells $744K of Stock
Amir Weiss, CAO, sold 17,289 shares of Teva Pharmaceutical Industries Ltd at $43.03 to $43.15 a share (average $43.04) in 3 transactions, worth $744K in total on Nov 9, 2026. Shares held after the trade: 3,537 (-72.9%).
- Value
- $744K
- Shares
- 17,289
- Average price
- $43.04
- Role
- CAO
- Holding change
- -72.9%
- Trade date
- Nov 9, 2026
Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.93M of Stock
Mark Sabag, See "Remarks", sold 46,000 shares of Teva Pharmaceutical Industries Ltd at $41.93 a share, worth $1.93M in total on Nov 5, 2026. Shares held after the trade: 80,760 (-36.3%).
- Value
- $1.93M
- Shares
- 46,000
- Price
- $41.93
- Role
- See "Remarks"
- Holding change
- -36.3%
- Trade date
- Nov 5, 2026
Teva Pharmaceutical Industries Interim Cheif Legal Officer Dov Bergwerk Sells $1.1M of Stock
Dov Bergwerk, Interim Cheif Legal Officer, sold 26,260 shares of Teva Pharmaceutical Industries Ltd at $41.72 a share, worth $1.1M in total on Nov 4, 2026. Shares held after the trade: 11,943 (-42.3%).
- Value
- $1.1M
- Shares
- 26,260
- Average price
- $41.72
- Role
- Interim Cheif Legal Officer
- Holding change
- -42.3%
- Trade date
- Nov 4, 2026